Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53482
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRolan, P.en
dc.contributor.authorSargentini-Maier, M.en
dc.contributor.authorPigeolet, E.en
dc.contributor.authorStockis, A.en
dc.date.issued2008en
dc.identifier.citationBritish Journal of Clinical Pharmacology, 2008; 66(1):71-75en
dc.identifier.issn0306-5251en
dc.identifier.issn1365-2125en
dc.identifier.urihttp://hdl.handle.net/2440/53482-
dc.description© 2008 The Authors; Journal compilation © 2008 Blackwell Publishing Ltden
dc.description.abstractWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The pharmacokinetic profile, metabolism and proof of concept of a single oral dose of brivaracetam have been reported. • Previous studies have shown that it was well absorbed, had linear kinetics and was well tolerated, and suggested effective doses of 10–80 mg in photoparoxysmal epilepsy. WHAT THIS STUDY ADDS • We now report the pharmacokinetics, pharmacodynamics and tolerability in healthy volunteers after multiple doses. AIMS Brivaracetam is a novel synaptic vesicle protein 2A ligand that has shown potent activity in animal models of epilepsy. This study examined the pharmacokinetics, central nervous system pharmacodynamics and adverse event profile of multiple oral doses of brivaracetam in healthy male subjects. METHODS Three successive panels of 12 healthy male subjects received double-blind brivaracetam 200, 400 or 800 mg day−1 (all doses well above the expected therapeutic range) or placebo (9 : 3), in two divided doses, for 14 days. RESULTS Brivaracetam was rapidly absorbed (tmax∼2 h) and eliminated (t1/2 7–8 h). Volume of distribution was slightly lower than total body water. A small fraction of the dose (5–8%) was excreted unchanged in urine together with significant levels of metabolites, suggesting predominantly metabolic clearance. Based on 6-β-hydroxycortisol/cortisol ratios in urine, there was no evidence of induction of CYP3A4 activity. Saliva and plasma brivaracetam levels were highly correlated. Adverse events were mostly mild to moderate, central nervous system-related and resolved within the first day of treatment. No clinically relevant changes were observed in laboratory tests, vital signs, physical examinations or ECGs. Pharmacodynamic tests showed dose-related sedation and decreased alertness that only persisted at 800 mg daily. CONCLUSIONS Brivaracetam was well tolerated by healthy male volunteers at doses of 200–800 mg daily for 2 weeks, well above the expected clinically effective dose range. Brivaracetam had a favourable pharmacokinetic profile in this population, characterized by rapid absorption, volume of distribution limited to total body water, apparent single-compartment elimination and dose proportionality.en
dc.description.statementofresponsibilityPaul Rolan, Maria Laura Sargentini-Maier, Etienne Pigeolet and Armel Stockisen
dc.language.isoenen
dc.publisherBlackwell Publishing Ltden
dc.subjectantiepileptics; brivaracetam; pharmacodynamics; pharmacokinetics; tolerability; ucb 34714en
dc.titleThe pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menen
dc.typeJournal articleen
dc.identifier.rmid0020083969en
dc.identifier.doi10.1111/j.1365-2125.2008.03158.xen
dc.identifier.pubid41035-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.